LONDON — Lars Fruergaard Jørgensen, who led Novo Nordisk because it rode the growth of its weight problems and diabetes drugs to develop into one of many greatest gamers in pharma, solely to see that success stall in latest months, is stepping down as CEO, the corporate mentioned Friday.
Jørgensen, who’s labored at Novo for greater than 30 years and has been CEO for eight, will proceed within the place for a interval “to assist a clean transition to new management,” the corporate mentioned.
The seek for the following CEO is ongoing.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
